

Innovative Biosensors, Inc. Establishes Scientific Advisory Board

College Park, MD, September 19, 2005 – Innovative Biosensors, Inc (IBI), a company developing rapid, ultra-sensitive tests to detect harmful pathogens, today announced the establishment of its Scientific Advisory Board.

Innovative Biosensors, Inc. develops and manufactures pathogen tests for infectious diseases within the food safety and human clinical markets. IBI has established a Scientific Advisory Board of prominent individuals with exceptional experience in both of these markets. The Board includes Dr. Arnold N. Weinberg and Dr. Edward R. Richter.

A Professor of Medicine at Harvard and Senior Physician at Massachusetts General Hospital, Dr. Weinberg has served the School and Hospital in a variety of capacities. At the Medical School, he was responsible for courses in microbiology, pathophysiology of infectious diseases and clinical infectious disease. At Massachusetts General Hospital, he was Vice Chair of Medicine, and, for over 4 decades, he has taught and consulted in general medicine and infectious disease. In addition, he served as Medical Director at Massachusetts Institute of Technology and continues to consult at MIT's Lincoln Laboratory and is a member of the Board of Directors at the Whitehead Institute for Biomedical Research. Dr. Weinberg's publications include over 70 articles and text chapters on a wide range of infectious disease subjects.

Dr. Richter is considered an expert in food quality, safety, and defense. Dr. Richter's specific area of expertise is in the area of food microbiological diagnostics. Dr. Richter founded Silliker Laboratories of Ohio, Inc., a food analytical service laboratory, as well as Richter International, Inc., an independent food safety, quality and defense research-consulting group, which has an alliance with Battelle Memorial Institute, the largest research institute in the world. In addition, Dr. Richter maintains his faculty status at The Ohio State University Departments of Food Science & Technology and Microbiology. He has published more than 30 research articles and three book chapters.

“IBI's research and development and marketing efforts will greatly benefit from the scientific guidance of Dr. Weinberg and Dr. Richter,” said Joe Hernandez, IBI's President and CEO. “Both are highly regarded in their respective clinical and food safety fields, and we are honored that they have agreed to serve on our Scientific Advisory Board.”

About Innovative Biosensors, Inc.

Innovative Biosensors, Inc. is a privately held company developing novel technologies for the rapid detection of pathogens. The company's technology is expected to have broad applications in food testing, animal health, and human health care, including drug discovery and development and disease diagnosis. IBI currently offers an *E. coli* O157:H7 Detection Kit for ground beef, food surface, and fruit/vegetable testing and plans to offer tests for additional pathogens in the near future. Additional information is available at www.innovativebiosensors.com

This release may contain forward-looking statements that are subject to certain risks and uncertainties, including Innovative Biosensors' mission to develop and commercialize instrument systems, Innovative Biosensors' ability to develop new technologies to conduct rapid diagnosis. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Innovative Biosensors cautions investors that there can be no

assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: Innovative Biosensors' expectations that they will incur operating losses in the near future, the early stage of development of Innovative Biosensors' products and technologies, uncertainties related to preclinical and clinical testing and trials, uncertainties surrounding the availability of additional funding, Innovative Biosensors' reliance on research collaborations, the actions of competitors and the development of competing technologies, potential patent infringement claims against Innovative Biosensors' products, processes and technologies, Innovative Biosensors' ability to protect their patents and proprietary rights and uncertainties relating to commercialization rights.

Contact:
Innovative Biosensors, Inc.
Hollie Kephart, Media Relations
Phone: (301) 405-8444
info@innovativebiosensors.com